Actually, combination treatment with the anti-programmed death-ligand 1 (PD-L1) monoclonal antibody atezolizumab plus the anti-vascular endothelial growth factor (VEGF) agent bevacizumab (Atezo/Bev) demonstrated prognostic superiority over sorafenib therapy in a phase III trial and was globally approved in 2020 as a primary systemic chemotherapy for unresectable HCC [13]. Here, CD274 is linked to hepatocellular carcinoma.